Patents Issued in February 25, 2021
  • Publication number: 20210052581
    Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
    Type: Application
    Filed: August 2, 2020
    Publication date: February 25, 2021
    Inventors: Jian ZHANG, Ying Wu, Rui Ling, Suning Chen, Lu Han, Wenxia Zhou
  • Publication number: 20210052582
    Abstract: Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Applicants: Portola Pharmaceuticals, Inc., ORA, Inc.
    Inventors: Anjali PANDEY, Matthew CHAPIN, Harold PATTERSON, Yung Yueh HSU, Mark ABELSON
  • Publication number: 20210052583
    Abstract: Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of cancer using a tubulin polymerization inhibitor such as a compound of formula I, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof, are provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: February 25, 2021
    Inventors: Marita HÖGBERG, Stefan REHNMARK
  • Publication number: 20210052584
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: March 31, 2020
    Publication date: February 25, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Publication number: 20210052585
    Abstract: The present invention includes substituted 3,3?bis(phenoxymethyl)-1,1?-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: March 29, 2019
    Publication date: February 25, 2021
    Inventors: Yingzhi Bi, Bruce D. Dorsey, Yi Fan, Christopher Brooks Moore, Duyan Nguyen
  • Publication number: 20210052586
    Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.
    Type: Application
    Filed: August 22, 2020
    Publication date: February 25, 2021
    Inventors: Ayman KABAKIBI, Mehmet KAHRAMAN, Michael CLARE, Thomas LEEDOM
  • Publication number: 20210052587
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Application
    Filed: April 17, 2019
    Publication date: February 25, 2021
    Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
  • Publication number: 20210052588
    Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.
    Type: Application
    Filed: November 9, 2020
    Publication date: February 25, 2021
    Inventors: Peter De Boer, Justine M. Kent, Wayne C. Drevets
  • Publication number: 20210052589
    Abstract: The present invention relates to a compound of the following formula (I): (I) or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of Alzheimer's disease in an individual.
    Type: Application
    Filed: March 7, 2019
    Publication date: February 25, 2021
    Applicant: Amabiotics
    Inventors: Patrice Garnier, Antoine Danchin
  • Publication number: 20210052590
    Abstract: The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).
    Type: Application
    Filed: July 28, 2020
    Publication date: February 25, 2021
    Applicant: Rutgers, the State University of New Jersey
    Inventor: Mark C. Siracusa
  • Publication number: 20210052591
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Application
    Filed: December 24, 2018
    Publication date: February 25, 2021
    Inventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
  • Publication number: 20210052592
    Abstract: The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
    Type: Application
    Filed: February 7, 2019
    Publication date: February 25, 2021
    Inventors: Clet NIYIKIZA, Victor Mandla MOYO
  • Publication number: 20210052593
    Abstract: Described are methods for the treatment of individuals having or as risk for having Macrophage Activation Syndrome (MAS). The disclosed methods may include the steps of detecting a tripartite motif 8 (TRIM8) protein level or a tripartite motif 8 (TRIM8) mRNA level in abiological sample obtained from an individual, and providing a treatment to said individual based on the level of TRIM8 protein and/or mRNA detected. Individuals identified as being high risk for MAS may be treated with an immunosuppressive therapy as disclosed herein.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Inventors: Alexei Grom, Grant Schulert
  • Publication number: 20210052594
    Abstract: The invention is directed to a method of treatment for pain, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 21, 2020
    Publication date: February 25, 2021
    Applicant: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard, Andrew Morgan Stewart
  • Publication number: 20210052595
    Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.
    Type: Application
    Filed: December 7, 2016
    Publication date: February 25, 2021
    Inventors: Stephen BLAKEMORE, Scott Richard DAIGLE
  • Publication number: 20210052596
    Abstract: Described herein are methods and compositions for the treatment of cancer. Aspects include administering (1) an agent that inhibits activity of a CBM signalosome complex, or (2) a cell engineered to have reduced CBM signalosome complex levels to a subject having cancer. In various embodiment, the methods further comprise administering second therapeutic, for example, a checkpoint inhibitor or anti-cancer therapy, to the subject.
    Type: Application
    Filed: December 28, 2018
    Publication date: February 25, 2021
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Thorsten R. MEMPEL, Mauro DI PILATO
  • Publication number: 20210052597
    Abstract: Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 25, 2021
    Inventors: Rajiv SHARMA, Pravin IYER, Jigar DESAI, Sanjay S. KUMAR
  • Publication number: 20210052598
    Abstract: The present disclosure features compositions and methods of treating a cancer in a subject by administering to the subject a Skp2 inhibitor and an inhibitor of glycolytic metabolism (e.g., PKM2 inhibitor).
    Type: Application
    Filed: March 6, 2019
    Publication date: February 25, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Wenyi Wei
  • Publication number: 20210052599
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: November 10, 2020
    Publication date: February 25, 2021
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • Publication number: 20210052600
    Abstract: The present invention provides a medicament for use in treating stress urinary incontinence with fewer adverse effects including a body weight lowering effect. The present invention also provides a medicament for use in treating a disease such as incontinence of feces and further provide a medicament for use in treating a disease such as incontinence of feces with fewer adverse effects including a body weight lowering effect. A medicament for use in treating stress urinary incontinence, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug. A medicament for use in treating incontinence of feces, etc., comprising a 5-HT2C receptor agonist. A medicament for use in treating incontinence of feces, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug.
    Type: Application
    Filed: December 27, 2018
    Publication date: February 25, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Izumi Kamo, Nele MUELLER-PLOCK
  • Publication number: 20210052601
    Abstract: Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine-containing ligand frameworks capable of anchoring to Pt via more than one binding site and with the phenanthridinyl moiety co-planar to the coordination plane of Pt. The multidentate chelation is designed to attenuate the reactivity of the platinum complex in vivo, and ultimately help mitigate side effects. In addition, the geometry of phenanthridine binding to the metal centre is altered compared to in phenanthriplatin, thanks to the constraints of the ligand geometry. By enforcing coplanar binding with the metal's square planar coordination plane, these compounds exhibit altered modes of activity, and should hence enhance/change the spectrum of activity of our prodrug candidates compared with phenanthriplatin.
    Type: Application
    Filed: May 24, 2019
    Publication date: February 25, 2021
    Inventors: David E. Herbert, Issiah B. Lozada, Bin Huang, Yaorong Zheng, Zihan Qiu
  • Publication number: 20210052602
    Abstract: Disclosed herein, in part, are pharmaceutical compositions comprising an opioid agonist such as codeine or a pharmaceutically acceptable salt thereof, hydroxyzine or a pharmaceutically acceptable salt thereof, a gabapentinoid, optionally a 5-HT3 antagonist and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: January 7, 2019
    Publication date: February 25, 2021
    Inventor: Dennis J. Bonner
  • Publication number: 20210052603
    Abstract: Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 25, 2021
    Inventors: Raymond F. Schinazi, Bryan COX, Chofit CHAI, Hilla GILADI, Eithan GALUN, Franck AMBLARD
  • Publication number: 20210052604
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Application
    Filed: April 8, 2020
    Publication date: February 25, 2021
    Applicant: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Publication number: 20210052605
    Abstract: Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular injection.
    Type: Application
    Filed: July 6, 2020
    Publication date: February 25, 2021
    Inventor: Mahendra G. SHAH
  • Publication number: 20210052606
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 25, 2021
    Inventors: John M. MCCALL, Eric HOFFMAN, Kanneboyina NAGARAJU
  • Publication number: 20210052607
    Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.
    Type: Application
    Filed: August 22, 2019
    Publication date: February 25, 2021
    Applicant: Nanopharmaceutics, Inc.
    Inventor: James Talton
  • Publication number: 20210052608
    Abstract: Disclosed herein are methods of treating carbapenem-resistant bacterial infections in a subject using various dosages of minocycline.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 25, 2021
    Applicant: Melinta Therapeutics, Inc.
    Inventors: Karen FUSARO, David C. GRIFFITH, Jeffrey S. LOUTIT
  • Publication number: 20210052609
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 25, 2021
    Applicants: Paratek Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Publication number: 20210052610
    Abstract: Provided is a method of treating or lessening the severity of pain in a subject, comprising administering to the subject a compound of formula (I), defined as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 12, 2019
    Publication date: February 25, 2021
    Inventors: Sagar AGARWAL, Cynthia BARBER, Francoise BERLIOZ-SEUX, Brenda CIRINCIONE, James JONES, Sandra LECHNER, Marco RIZZO, David STILES
  • Publication number: 20210052611
    Abstract: In various embodiments methods are provided for the treatment or prophylaxis of liposomal storage diseases. In certain embodiments the methods involve administering to a subject in need thereof one or more molecular tweezers that inhibit protein aggregation.
    Type: Application
    Filed: April 25, 2019
    Publication date: February 25, 2021
    Applicants: The Regents of the University of California, Fondazione Telethon, Fondazione Telethon
    Inventors: Gal Bitan, Alessandro Fraldi, Irene Sambri, Antonio Monaco
  • Publication number: 20210052612
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 25, 2021
    Inventors: Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG
  • Publication number: 20210052613
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Application
    Filed: May 22, 2020
    Publication date: February 25, 2021
    Inventors: Byoung Kwon Chun, Michael O' Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Publication number: 20210052614
    Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.
    Type: Application
    Filed: November 3, 2020
    Publication date: February 25, 2021
    Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
  • Publication number: 20210052615
    Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.
    Type: Application
    Filed: November 9, 2020
    Publication date: February 25, 2021
    Inventors: Emma Salomonsson, Bruce McConnell, Thierry Hennet, Louise Kristine Vigsnæs
  • Publication number: 20210052616
    Abstract: The invention relates to a new form of a drug in the form of anthracycline encapsulated with a polysaccharide selected from epirubicin, daunorubicin, doxorubicin, idarubicin, especially encapsulated with dextran, for use in the treatment of specific tumours.
    Type: Application
    Filed: March 5, 2019
    Publication date: February 25, 2021
    Applicant: NanoVelos S.A
    Inventors: Iga WASIAK, Tomasz CIACH, Aleksandra KULIKOWSKA-DAR?AK, Piotr PIETRZAK, Agnieszka SOBIECKA, Wioletta KOSNIK, Joanna PIETRAS, Pawel ZERO, Pawel ZUK, Justyna MALKOWSKA, Kinga ADAMSKA, Mikolaj CHROMINSKI, Adam KICIAK
  • Publication number: 20210052617
    Abstract: Methods and compositions using trehalose or a derivative or prodrug thereof for treating pre-eclampsia in a subject are disclosed.
    Type: Application
    Filed: January 16, 2019
    Publication date: February 25, 2021
    Inventor: Surendra Sharma
  • Publication number: 20210052618
    Abstract: A formulation includes microcapsules which contains a core containing an extract rich in glucosinolates obtained from crucifers and a biopolymer, and an enteric coating containing myrosinase and a biopolymer. A procedure is to obtain the same and to use the formulation as such, or in dietetic food supplements for humans or animals due to its immunostimulant activity.
    Type: Application
    Filed: November 9, 2020
    Publication date: February 25, 2021
    Inventors: Jessica SÁENZ GÓMEZ, Laura OLIVER GARCÍA, María Carmen VILLARÁN VELASCO
  • Publication number: 20210052619
    Abstract: Provided are methods and compositions for treating cachexia in order to reduce the morbidity and mortality of chronic illnesses and to improve the effectiveness of treating chronic illness overall. More specifically, provided herein are methods and compositions for treating cachexia by agents that modulate the immune system and/or inflammation.
    Type: Application
    Filed: January 15, 2018
    Publication date: February 25, 2021
    Inventors: Lingbing Zhang, Dongxu Zhang
  • Publication number: 20210052620
    Abstract: The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.
    Type: Application
    Filed: January 18, 2019
    Publication date: February 25, 2021
    Inventors: Avi AVRAMOFF, Helena SHIFRIN, Ron SCHLINGER, Tzviel SHESKIN, Zeev ELKOSHI
  • Publication number: 20210052621
    Abstract: There are provided, inter alia, methods of treatment of Zika virus infection.
    Type: Application
    Filed: January 17, 2018
    Publication date: February 25, 2021
    Inventor: Tariq M. Rana
  • Publication number: 20210052622
    Abstract: Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 25, 2021
    Inventor: Massimo IACOBELLI
  • Publication number: 20210052623
    Abstract: The present invention relates to a liquid composition containing a high concentration of a DNA fragment mixture and a preparation method therefor. A liquid composition containing a high concentration of a DNA fragment mixture and having fluidity was prepared. The liquid composition that contains a high concentration of a DNA fragment mixture and has fluidity was identified to maintain a pharmaceutical activity, have high stability even during long-term storage, and be effectively injectable to the human body, whereby a high concentration of a DNA fragment mixture having fluidity is expected to be applicable to the development of various formulations such as injections, liquid agents, creams, and the like.
    Type: Application
    Filed: March 7, 2019
    Publication date: February 25, 2021
    Applicant: PHARMARESEARCH PRODUCTS CO., LTD.
    Inventors: Ik Soo KIM, Su Yeon LEE
  • Publication number: 20210052624
    Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 25, 2021
    Applicant: Arrowhead Pharmaceuticals, Inc.
    Inventors: Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
  • Publication number: 20210052625
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: September 14, 2020
    Publication date: February 25, 2021
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Publication number: 20210052626
    Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
    Type: Application
    Filed: November 5, 2020
    Publication date: February 25, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Idit SHACHAR, Hadas LEWINSKY, Lihi RADOMIR, Anna WIENER
  • Publication number: 20210052627
    Abstract: The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.
    Type: Application
    Filed: March 30, 2018
    Publication date: February 25, 2021
    Inventors: Xin Wu, Masaki Mori, Hirofumi Yamamoto
  • Publication number: 20210052628
    Abstract: The present invention concerns an in vivo method for introducing an mRNA molecule (which is not associated with a carrier) into the cytosol of a cell(s) in a subject, by the use of photochemical internalization, wherein the photosensitising agent is a sulphonated meso-tetraphenyl chlorin, sulfonated tetraphenylporphine or a di- or tetrasulfonated aluminium phthalocyanine used in an amount of 0.0001 to 1 ?g. The method may be used to express a polypeptide in the subject. The invention is also directed to pharmaceutical compositions containing the photosensitising agents and the mRNA and uses of the molecules in therapy, e.g. to treat or prevent cancer or an infection.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 25, 2021
    Applicant: PCI Biotech AS
    Inventor: Anders HØGSET
  • Publication number: 20210052629
    Abstract: The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of the following a) to d): a) an RNA comprising, in this order, a nucleotide sequence of a first mitochondrial tRNA, a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a second mitochondrial tRNA, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon; b) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of a); c) an RNA comprising a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a poly(A) chain present at the 3? end side thereof, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon, AUG as a start codon, and UAA as a stop codon; and d) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of c).
    Type: Application
    Filed: February 25, 2019
    Publication date: February 25, 2021
    Applicant: LUCA Science Inc.
    Inventors: Hideyoshi HARASHIMA, Yuma YAMADA, Kana SOMIYA, Hitoshi OSAKA
  • Publication number: 20210052630
    Abstract: Application of transfer RNA Molecules and their derived fragments for prevention or treatment of heart disease. The present invention provides a method of preventing or treating a subject suffering from heart diseases comprising administration of transfer RNA molecules and fragments derived from transfer RNA molecules or its functional variants or homologous to the subject, wherein the RNA molecules isolated from or derived from a plant of the genus Panax. The present invention also provides a pharmaceutical composition for the prevention or treatment of heart diseases comprising said effective amount of RNA molecule and a pharmaceutically tolerable vector, virus or excipient. The present invention provides a method for the prevention or treatment of a subject suffering from a heart disease. It is found that transfer RNA molecules from ginseng are particularly effective in the treatment of heart diseases, and also have a restorative effect on the myocardial cytoskeleton after ischemia-reperfusion injury.
    Type: Application
    Filed: August 20, 2020
    Publication date: February 25, 2021
    Inventors: Zhi-Hong JIANG, Kua HU, Tong-Meng YAN